First human test: gene injection aims to halt blinding eye disease
NCT ID NCT07002398
Summary
This is an early safety study testing a new gene therapy called VG801 for people with Stargardt disease, an inherited condition that causes vision loss. The trial will enroll 15 participants, aged 6 and older, who have specific genetic mutations. Doctors will inject the experimental therapy once directly under the retina to see if it is safe and if it might help slow or stop the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STARGARDT DISEASE 1 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai General Hospital
RECRUITINGShanghai, Shanghai Municipality, 200080, China
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.